Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ107MR)

This product GTTS-WQ107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ107MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14008MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ2698MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ12476MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ4064MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ5462MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ1535MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ14317MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ1083MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-838
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW